UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available.

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) yesterday and set a price target of €240.00. The ...

The upcoming report from United Community Banks (UCB) is expected to reveal quarterly earnings of $0.56 per share, indicating an increase of 5.7% compared to the year-ago period. Analysts forecast ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

UCB Investment Limited has successfully closed the “SJIBL 3rd Mudaraba Subordinated Bond” worth Tk 500 crore, issued by ...

UCB Investment Limited has successfully closed the SJIBL 3rd Mudaraba Subordinated Bond of Tk500 crore, issued by Shahjalal ...

United Community Banks (UCB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug discovery, today announced a license ...

GET MORE AI-GENERATED SIGNALS: January 10, 2025, 13:48 pm ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Belgian drugmaker UCB has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at ...